Posted by Michael Wonder on 02 May 2025
DoH publishes revised agenda for the May 2025 PBAC meeting
2 May 2025 - The agenda for the May 2025 PBAC meeting has been updated.
The revised agenda notes three new submissions:
- Nivolumab (Opdivo) and ipilimumab (Yervoy) - restriction change
- Pioglitazone hydrochloride (Actos) - Restriction change
- Teprotumumab (Tepezza) - new medicine
